Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL

Inclusion Criteria: * Histologically confirmed diagnosis of indolent B-cell NHL, with histological subtype limited to the following: Follicular lymphoma (FL) grade 1-2-3a Small lymphocytic lymphoma (SLL) with absolute lymphocyte count \< 5 x 109/L at the time of diagnosis and at study entry Lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia (LPL/WM) Marginal zone lymphoma (MZL) (splenic, nodal, or extra-nodal) * Relapsed or refractory after ≥ 2 prior lines of therapy (refractory defined as not responding to a standard regimen or progressing within 6 months of the last course of a standard regimen). Patients must have previously received rituximab and alkylating agent(s). * Japanese patients ≥ 20 years of age * ECOG performance status ≤ 2 (Eastern Cooperative Oncology Group:ECOG) * Life expectancy of at least 3 months * Adequate bone marrow, liver and renal function as assessed within 7 days before starting study treatment * Left ventricular ejection fraction (LVEF) ≥ lower limit of normal (LLN) for the Institution * Availability of fresh or archival tumor tissue Exclusion Criteria: * Uncontrolled hypertension (blood pressure ≥ 150/90 mmHg, defined as systolic blood pressure \> 150 mmHg and/or diastolic blood pressure \> 90 mmHg, despite optimal medical management) * Patients with evidence or history of bleeding diathesis. Any hemorrhage or bleeding event ≥ CTCAE Grade 3 (NCI-CTC version 4.0) within 4 weeks of start of study medication (CTCAE: Common Terminology Criteria for Adverse Events, NCI: National Cancer Institute). * History or concurrent condition of interstitial lung disease or severely impaired pulmonary function * Unresolved toxicity higher than CTCAE grade 1 attributed to any prior therapy/procedure excluding alopecia. * Prior treatment with PI3K inhibitors * Systemic corticosteroid therapy (ongoing) * Type I or II diabetes mellitus with HbA1c \> 8.5% or fasting plasma glucose \> 160 mg/dL at Screening * Known history of human immunodeficiency virus (HIV) infection. * Hepatitis B or C requiring treatment * Cytomegalovirus (CMV) PCR positive at baseline * Known lymphomatous involvement of the central nervous system